title: [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
abstract: We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.2 mg and solifenacin 5 mg (TS) for 8 weeks (group N) ; another 17 were initially prescribed TS, followed by N (group TS). The efficacy variables were the changes in international prostate symptom score (I-PSS), quality of life (QOL) score, overative bladder symptom score (OABSS), and post-void residual (PVR) urine volume. After the study, a questionnaire survey was carried out about the choice of treatment. After treatment with each agent, total I-PSS, storage symptom score, QOL score and OABSS except for the daytime frequency were significantly improved from baseline. PVR was significantly increased after TS treatment. There were no significant differences between the two treatments except for PVR. As a result of the questionnaire survey, 13 patients chose N and 17 chose TS. In conclusion, N monotherapy can be expected to have an equal effect in the treatment of LUTS with OAB secondary to BPH in comparison with TS combination therapy.
authors: The Department of Urology, Kobe City Medical Center General Hospital.
authors: Noriaki
authors: N
authors: Utsunomiya
authors: The Department of Urology, Kobe City Medical Center General Hospital.
authors: Keiyu
authors: K
authors: Matsumoto
authors: The Department of Urology, Kobe City Medical Center General Hospital.
authors: Hiroyuki
authors: H
authors: Tsunemori
authors: The Department of Urology, Kobe City Medical Center General Hospital.
authors: Koei
authors: K
authors: Muguruma
authors: The Department of Urology, Kobe City Medical Center General Hospital.
authors: Mutsushi
authors: M
authors: Kawakita
authors: The Department of Urology, Nishi-Kobe Medical Center.
authors: Yuki
authors: Y
authors: Kamiyama
authors: The Department of Urology, Nishi-Kobe Medical Center.
authors: Sojun
authors: S
authors: Kanamaru
authors: The Department of Urology, Nishi-Kobe Medical Center.
authors: Noriyuki
authors: N
authors: Ito
authors: The Department of Urology, National Hospital Organization Himeji Medical Center.
authors: Hideki
authors: H
authors: Tsukazaki
authors: The Department of Urology, National Hospital Organization Himeji Medical Center.
authors: Toshiaki
authors: T
authors: Shirahase
authors: The Department of Urology, Hyogo Prefectural Tsukaguchi Hospita.
authors: Takeshi
authors: T
authors: Takahashi
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D009281:Naphthalenes / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011788:Quality of Life; D000069464:Solifenacin Succinate / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D000077409:Tamsulosin; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D018727:Muscarinic Antagonists; D009281:Naphthalenes; D010879:Piperazines; D013449:Sulfonamides; D000077409:Tamsulosin; D000069464:Solifenacin Succinate; C064357:naftopidil